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Rhomboid intramembrane 
protease RHBDL4 triggers ER-
export and non-canonical secretion 
of membrane-anchored TGFα
Lina Wunderle1,*, Julia D. Knopf1,*, Nathalie Kühnle1, Aymeric Morlé2, Beate Hehn1, 
Colin Adrain3, Kvido Strisovsky2, Matthew Freeman4 & Marius K. Lemberg1
Rhomboid intramembrane proteases are the enzymes that release active epidermal growth factor 
receptor (EGFR) ligands in Drosophila and C. elegans, but little is known about their functions in 
mammals. Here we show that the mammalian rhomboid protease RHBDL4 (also known as Rhbdd1) 
promotes trafficking of several membrane proteins, including the EGFR ligand TGFα, from the 
endoplasmic reticulum (ER) to the Golgi apparatus, thereby triggering their secretion by extracellular 
microvesicles. Our data also demonstrate that RHBDL4-dependent trafficking control is regulated by 
G-protein coupled receptors, suggesting a role for this rhomboid protease in pathological conditions, 
including EGFR signaling. We propose that RHBDL4 reorganizes trafficking events within the early 
secretory pathway in response to GPCR signaling. Our work identifies RHBDL4 as a rheostat that tunes 
secretion dynamics and abundance of specific membrane protein cargoes.
Intramembrane proteases perform a wide range of important functions ranging from activation of 
membrane-tethered molecules to regulated protein degradation1. Rhomboids are intramembrane serine pro-
teases2, first described in Drosophila, where Rhomboid-1 was initially defined as the key regulator of epidermal 
growth factor receptor (EGFR) signaling3,4. Heterologous expression of Drosophila Rhomboid-1 in mammalian 
tissue culture cells illuminated its function in the release of growth factors. Rhomboid-1 cleaves the EGFR ligand 
Spitz in its transmembrane (TM) domain, thereby inducing secretion of the bioactive ligand and signaling to 
neighboring cells5. In addition to transcriptional control of rhomboid-16, this release pathway is mediated by reg-
ulated substrate trafficking. The transport factor Star guides Spitz from the endoplasmic reticulum (ER), thereby 
bringing it into contact with the Golgi-localized Rhomboid-1 protease5. A related function has been reported in 
C. elegans for the rhomboid protease ROM-1 in processing of the EGFR ligand LIN-3L7.
Despite widespread conservation of signaling pathways, this is a case where mammals use a different mecha-
nism: EGFR ligand processing in mammals is mainly driven by sheddases of the ADAM-type (‘a disintegrin and 
metalloprotease’)8, and EGFR ligand processing by rhomboids may have a modulatory effect only9. Transforming 
growth factor α (TGFα ), the best-characterized mammalian EGFR ligand, is activated by ADAM17, also known 
as TACE (‘TNFα converting enzyme’)10. Membrane-anchored TGFα moves to the plasma membrane accom-
panied by PDZ domain proteins, where ADAM17 cleaves it just outside its TM domain, releasing the active 
EGFR ligand11. Nonetheless, several reports indicate that processing and maturation of TGFα is more complex, 
including regulation by G-protein coupled receptor (GPCR) signaling12–14. Furthermore, in some contexts release 
of TGFα has been shown to be sensitive to serine protease inhibitors15. The rhomboid intramembrane protease 
RHBDL4 (also known by its gene name Rhbdd1) has been recently suggested to be an alternative shedding 
enzyme for TGFα at the plasma membrane16. This contrasts with an earlier report that showed that RHBDL4 
localizes to the ER, where it functionally interacts with the ER-associated protein degradation (ERAD) pathway17. 
1Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Allianz, Im Neuenheimer Feld 
282, 69120 Heidelberg, Germany. 2Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the 
Czech Republic, Prague, Czech Republic. 3Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 6, 2780-156, 
Oeiras, Portugal. 4Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, 
UK. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed 
to M.F. (email: matthew.freeman@path.ox.ac.uk) or M.K.L. (email: m.lemberg@zmbh.uni-heidelberg.de)
received: 02 March 2016
Accepted: 16 May 2016
Published: 06 June 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:27342 | DOI: 10.1038/srep27342
Figure 1. RHBDL4 triggers secretion of proTGFα in an ADAM protease-independent manner.  
(a) Schematic representation of pre-proTGFα . Position of the FLAG-tag used in this study is indicated. SPase, 
signal peptidase; grey hexagon, N-linked glycosylation site; TMD, TM domain. (b) Ectopically expressed 
RHBDL4 in Hek293T cells (and to a lower extent also RHBDL1) trigger generation of a 37-kDa form of 
proTGFα -FLAG (black arrow) that is secreted into the tissue culture supernatant. In contrast, the 28-kDa  
form lacking complex-type glycans in the pro-peptide is not significantly secreted (grey arrow). Secreted 
proTGFα -FLAG was detected at low level in absence of rhomboid overexpression, so that an overexposed  
blot is shown. Expression of ectopically expressed RHBDLs was detected by the HA-tag (right panel). The  
assay, except lane 1/7, was performed in the presence of 10 μ M BB94 to inhibit shedding by ADAM proteases. 
(c) EndoH and PNGaseF treatment of cell extracts shows that the 37-kDa form of proTGFα -FLAG (black arrow) 
is EndoH-insensitive demonstrating that it is localized to the late secretory pathway. In contrast, the 28-kDa 
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RHBDL4, which is phylogenetically distinct from the three other rhomboid proteases in the mammalian secre-
tory pathway18, has also been linked to other processes such as regulating apoptosis via c-Jun and exosome secre-
tion19,20. Overall, there is no clear consensus about the function in mammalian cells of RHBDL4.
In this study we set out to address the apparent discrepancy between the function of RHBDL4 in the ER 
and the protease’s putative role in TGFα biology. We find that RHBDL4 enhances ER-to-Golgi trafficking of the 
unprocessed, full-length TGFα but, contrary to a previous report16, does not directly contribute to its shedding. 
Unexpectedly, RHBDL4 regulates secretion of TGFα , and other cargoes, in extracellular microvesicles. This pro-
cess alters the balance between the canonical shedding pathway and an alternative pathway of microvesicle release 
of membrane tethered, inactive TGFα . Our data also reveal that RHBDL4 can be regulated by GPCR signaling, 
a process associated with EGFR transactivation. These observations suggest that RHBDL4 is a nexus integrating 
intercellular signals via GPCRs, tuning the signaling output by modulating secretory cargo trafficking.
Results
RHBDL4 can promote release of full-length proTGFα. There is evidence for an ADAM17-
independent secretion mechanism for TGFα , including activity sensitive to serine protease inhibitor 
3,4-dichloroisocoumarin (DCI)15,21 and a recently suggested link to RHBDL416. TGFα maturation is complex: 
prior to shedding of the active growth factor from the plasma membrane, TGFα also incurs cleavage of the 
N-terminal pro-domain, and a variety of modifications including N-linked glycosylation (Fig. 1a)11. We therefore 
set out to evaluate the impact of mammalian rhomboid proteases on TGFα biology in cell-based assays. We used 
the metalloprotease inhibitor BB94 to block both pro-peptide cleavage and shedding by ADAM proteases, and 
co-expressed FLAG-tagged proTGFα 16 with the four known mammalian secretory pathway rhomboid proteases 
in Hek293T cells (Fig. 1b). Surprisingly, RHBDL4 triggered extensive BB94-insensitive release of a 37-kDa form 
of proTGFα into the media, suggesting a secretion mechanism for full-length proTGFα , distinct from canonical 
shedding of the 6-kDa extracellular active ligand by ADAM proteases (see Fig. 1g). Shedding of a full-length 
37-kDa form was broadly specific to RHBDL4 (although RHBDL1, a Golgi enzyme, had a very slight similar 
effect) (Fig. 1b). Traces of a faster migrating species, which runs slightly above the 28-kDa species found in the 
cell extracts, were also secreted. The unexpected high molecular weight of both secreted forms implies that pro-
TGFα is not shed in a classical manner by the rhomboid proteases but instead is released as full-length protein 
(see below).
Using the deglycosylating enzymes EndoH and PNGaseF to distinguish ER- from Golgi-modified glycans in 
the cell extracts, we found that the 37-kDa form of proTGFα has been modified in the Golgi whereas the 28-kDa 
form represents the ER-resident species harboring only the core glycan structure (Fig. 1a,c). This result indicates 
that the secreted 37-kDa species, whose generation is enhanced by RHBDL4, is proTGFα that has passed through 
the Golgi apparatus.
Secretion of the 37-kDa TGFα species in cell extracts and media fraction was dependent on the active site 
serine of RHBDL4 (Fig. 1d), implying a requirement for the proteolytic activity of RHBDL4 to induce this 
non-canonical proTGFα secretion. In contrast, RHBDL4 did not affect S1P (site 1-protease), a type I membrane 
protein that upon overexpression is secreted by a BB94-sensitive shedding event (Fig. 1e), indicating that the 
effect is specific. Identical BB94-insensitive release of a higher molecular weight form of proTGFα was observed 
in HCT116, HeLa and COS7 cells (Fig. 1f and data not shown), demonstrating a mechanism general to a range of 
cell types. Overall, these results identify a previously unrecognized secretion mechanism for full-length proTGFα .
To test the relationship of this non-canonical secretion mechanism to EGFR signaling, we co-expressed 
untagged proTGFα with RHBDL4 and observed that RHBDL4 augmented the release of the higher MW species 
while reducing the amount of the 6-kDa secreted species. This is consistent with a role for RHBDL4 in remodeling 
the secretory fate of cargo proteins (Fig. 1g).
We next examined the activation of the EGFR by conditioned tissue culture supernatants (Fig. 1h). By using 
an antibody against the EGF domain of TGFα we also observed generation of a membrane-tethered 20-kDa 
TGFα species lacking the pro-peptide (subsequently described as TGFα -TMD) that is also secreted into the 
tissue culture supernatant (Fig. 1a,g and below). Neither secreted higher molecular weight form of TGFα acti-
vated the EGFR on medium starved A431 cells (Fig. 1h). Contrary to a previous report16, this indicated that 
TGFα released by RHBDL4 (in presence of BB94 to prevent canonical shedding) is not bioactive. In con-
trast to the RHBDL4-induced release of TGFα , when ADAM proteases were not inhibited, significantly less 
higher-molecular-weight proTGFα forms were detected, both in the cell extract and in the media fraction, and 
trimming to the 6-kDa mature growth factor was observed (Fig. 1a,g). This form efficiently activated the EGFR in 
A431 cells (Fig. 1h). Taken together, these results reveal an unexpected link of a rhomboid protease to trafficking 
and secretion of the unprocessed, full-length pro-form of an EGFR ligand.
species representing the ER form (grey arrow) is EndoH-sensitive. Dot, deglycosylated form. (d) Release of 
proTGFα -FLAG is specifically caused by rhomboid activity since the active site mutant of RHBDL1 (S247A) 
and RHBDL4 (S144A) show no significant effect. (e) Effect is specific to proTGFα -FLAG since FLAG-tagged 
S1P, which is cleaved by BB94-sensitive sheddase, is not released upon RHBDL4 overexpression. (f) Assay as in 
(b) using HCT116 cells. (g) Assay as in (b) using untagged proTGFα . Western blotting using a TGFα -specific 
antibody reveals in addition to higher MW form (black arrow) secretion of 20-kDa species lacking the pro-
peptide (TGFα -TMD) and mature 6-kDa TGFα . ProTGFα lacking complex type glycans (ER form) is not 
secreted. (h) Incubation of conditioned media from cell-based assay as in (g) with medium starved A431 cells 
shows that higher MW forms cannot efficiently activate the EGFR whereas mature TGFα observed in absence  
of BB94 leads to robust signaling. EGFR-P, phosphorylated EGFR; neg, A431 cells treated with fresh medium.
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Figure 2. RHBDL4 localizes to ER and rescues proTGFα from ERAD. (a) RHBDL4-GFP co-localizes 
to the ER marker RFP-KDEL in HCT116 cells. Scale bar, 5 μ M. (b) Fluorescent micrograph of HCT116 
cells co-expressing RHBDL2-GFP and RHBDL4-RFP. Scale bar, 5 μ M. (c) Immunofluorescence analysis of 
untransfected COS7 cells shows RHBDL4 co-localization with the ER protein BAP31. Scale bar, 5 μ M.  
(d) Metabolic pulse label and chase experiment shows that the 37-kDa proTGFα species is generated with a lag 
phase of 30 minutes, whereas lower molecular weight degradation intermediates (white arrow and grey dot) 
appear directly after the pulse and chase away over time. Asterisk, unspecific band. (e) Treatment of Hek293T 
cells ectopically expressing proTGFα -FLAG with the proteasome inhibitor MG132 (mg; 5 μ M) and epoxomicin 
(ep; 2 μ M) leads to massive increase of the 37-kDa species (black arrow) and to various unglycosylated forms 
(circles) indicating that it is degraded to a high extent by the ERAD pathway. Whereas the 37-kDa form is 
secreted, mimicking the effect caused by RHBDL4 overexpression, the lower molecular weight species are only 
detected in the cell lysates (grey and open symbols).
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RHBDL4 localizes to the ER in multiple cell lines. Next we asked, where in the secretory pathway 
RHBDL4 acts. The subcellular localization of RHBDL4 has been controversial. Although we previously observed 
that in Hek293T cells RHBDL4 localizes to the ER17, Wang and colleagues recently described plasma membrane 
localization of RHBDL4 in HCT116 cells by immunofluorescence analysis16. Since we have seen that formalde-
hyde fixation can impair immunofluorescence analysis of RHBDL4 (result not shown), we used living cells to 
assess RHBDL4 subcellular localization. We imaged HCT116 cells co-transfected with RHBDL4-GFP and the ER 
marker RFP-KDEL and detected complete co-localization (Fig. 2a). Consistent with this, we did not detect any 
overlap of RHBDL4-RFP with the plasma membrane-localized RHBDL2-GFP (Fig. 2b). Localization of RHBDL4 
to the ER was further corroborated by immunofluorescence analysis of endogenous RHBDL4 in acetone fixed 
COS7 cells (Fig. 2c). Although these results formally do not rule out that a subfraction of RHBDL4 could be else-
where in some contexts, we conclude that the predominant localization of endogenous and ectopically expressed 
RHBDL4 is the early secretory pathway.
RHBDL4 redirects proTGFα from proteasomal degradation towards secretion. To find 
out whether RHBDL4-induced increase of intracellular proTGFα is caused by increased biosynthesis rate or 
decreased degradation, we performed a pulse-chase analysis. Directly after a pulse label in cells transfected with 
FLAG-tagged TGFα , the 28-kDa ER pro form and traces of a lower molecular weight species were detected 
(Fig. 2d). With a half-life shorter than 20 minutes this species decreased and only traces of the 37-kDa mature 
species were generated. Since the experiment was performed in presence of BB94, blocking ADAM-mediated 
maturation and shedding, we conclude that proTGFα is degraded. In contrast, in cells co-expressing RHBDL4, 
the 28-kDa form almost quantitatively converted to the 37-kDa species, indicating that the effect is caused by 
increased ER export and subsequent addition of Golgi modifications. Moreover, slightly more of a 22- and 26-kDa 
species were detected. However, in contrast to the 37-kDa form that is generated with a lag phase of 30 minutes 
and increases at 120 minutes, the lower molecular weight species were already present directly after the pulse 
and rapidly chased away, suggesting that they represent degradation intermediates caused by defective synthesis. 
Consistent with a previous report22 we observed, using proteasome inhibitors, that tagged proTGFα is highly 
susceptible to proteasomal degradation (Fig. 2e). This demonstrates that under steady state conditions the major-
ity of FLAG-tagged proTGFα does not leave the ER but is degraded by the ERAD pathway. However, ectopic 
expression of RHBDL4 or inhibition of the proteasome changes this fate, increasing ER export, and resulting in 
secretion of the higher molecular weight form (Fig. 2e). This indicates that the majority of proTGFα is properly 
folded and has the potential to pass the ER quality control machinery, implying that this is a case of ERAD being 
used as a signal regulator rather than a quality control process. This adds to a growing number of cases of this con-
cept23–26. Expression of RHBDL4 in presence of proteasome inhibitors increased secretion even further (Fig. 2e), 
indicating that turnover of proTGFα by the ERAD pathway and the RHBDL4-induced ER export are based on 
two independent mechanisms.
ER export and non-canonical secretion of proTGFα are mediated by its cytoplasmic 
PDZ-binding domain. ER export and subsequent trafficking of proTGFα has previously been shown to be 
a regulated process, with various cytoplasmic regulatory factors including PDZ-domain proteins recognizing its 
C-terminal tail and thereby controlling its trafficking11. To test the role of these trafficking signals, we generated 
truncated proTGFα constructs lacking either the PDZ-binding domain (Δ 4) or the entire cytoplasmic tail (Δ 31) 
and compared their fate to the full-length protein (Fig. 3a). Consistent with previous reports27,28, almost no higher 
molecular weight species were detected for either mutant, even when pro-peptide cleavage was blocked by BB94, 
indicating that they do not efficiently leave the ER. Co-expression of RHBDL4 only marginally promoted traffick-
ing of the deletion mutants, judged by the presence of higher molecular weight species. Whereas traces of proT-
GFα Δ 4 were detected in the media fraction, no release of proTGFα Δ 31 was observed. These results indicate that 
the cytoplasmic tail and the PDZ-binding domain of proTGFα are needed for RHBDL4 to promote trafficking 
and secretion.
Consistent with the release of proTGFα not being caused by RHBDL4-catalysed canonical shedding, muta-
tion of all small and unbranched amino acids in the juxtamembrane region of proTGFα , which represent poten-
tial rhomboid recognition and cleavage sites29, had no significant effect on RHBDL4-induced maturation and 
secretion (Fig. 3b). Recently Song et al. suggested that in HCT116 cells RHBDL4 cleaves proTGFα at Ala-93 in 
the juxtamembrane region16. To examine this idea, the A93F and A93P mutants, which are predicted to block 
any rhomboid-mediated proteolysis at this putative site29, were expressed in presence of RHBDL4. As shown in 
Fig. 3c, using HCT116 cells, these mutants had no effect on secretion of the 37-kDa proTGFα form and several 
lower molecular weight species. Importantly, we also detected traces of a 17-kDa species that Song et al. referred 
to as RHBDL4-generated cleavage fragment16 in the media fraction. However, in contrast to this previous report, 
we observed that the presence of this species was not affected by rhomboid proteolysis, as equal amounts of it 
were generated in the presence of catalytically inactive RHBDL4 S144A. Moreover, none of the putative cleavage 
site mutants affected production of this species.
These findings support our conclusion that the RHBDL4-mediated release of TGFα is not caused by 
rhomboid-mediated shedding of the extracellular domain. Our finding that TGFα is not a RHBDL4 substrate is 
further supported by domain swap experiments with the stable ER protein calnexin, which we previously showed 
to resist cleavage by ectopically expressed RHBDL417. Replacement of the proTGFα TM domain by the calnexin 
TM domain did not affect RHBDL4 induced maturation and secretion (Fig. 3d). Furthermore, we did not co-purify 
any proTGFα with the catalytic S144A mutant of RHDBL4, which we previously showed to act as a substrate 
trap for the unstable orphan α -subunit of the pre-T cell receptor (pTα ) (Fig. 3e)17. Taken together, these results 
strongly support the conclusion that RHBDL4 does not cleave proTGFα but instead modulates its intracellular 
trafficking and subsequent release by an unknown mechanism, albeit one that is dependent on RHBDL4 protease 
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Figure 3. Non-canonical proTGFα secretion is mediated by its cytoplasmic tail and not the juxtamembrane 
region. (a) Deletion of carboxy-terminal PDZ-binding domain (Δ 4) reduces secretion of proTGFα , whereas 
deletion of the entire cytoplasmic tail (Δ 31) completely prevents its release. (b) Secretion of proTGFα triggered 
by RHBDL4 ectopically expressed in Hek293T cells is unaffected by mutations of putative rhomboid-like cleavage 
sites in the juxtamembrane and adjacent TM region of FLAG-proTGFα . (c) Mutation of A93F and A93P do not 
prevent RHBDL4-induced secretion of proTGFα and secretion of a 17-kDa proTGFα fragment (indicated by 
asterisk) is independent of RHBDL4 activity in HCT116 cells. (d) RHBDL4-triggered non-canonical proTGFα 
secretion does not depend on membrane integral features shown by expression of a chimeric molecule harboring 
the TM domain of the stable ER protein calnexin (proTGFα -CNXTMD). (e) The active site S144A mutant of 
RHBDL4-GFP (SA) co-immunoprecipitates the ERAD substrate pTα but not proTGFα . Mutation of L274A and 
L278A (mt) in the conserved ubiquitin interacting motif of RHBDL4 reduce binding of pTα as has been observed 
previously17. IP, immunoprecipitation; WB, western blot. (f) Carboxy-terminal tail of proTGFα is sufficient for 
non-canonical secretion as demonstrated by the chimeric molecule CNX-TGFα tail.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:27342 | DOI: 10.1038/srep27342
activity. Consistent with this hypothesis, fusing the ER protein calnexin to the cytoplasmic tail of proTGFα  
is sufficient to allocate calnexin to the RHBDL4 (and RHBDL1) dependent secretion mechanism (Fig. 3f).
RHBDL4 enhances ER export of a wide range of membrane proteins. Next we asked whether 
the RHBDL4-mediated effect was specific to the trafficking of proTGFα , or if the effect is more widespread. 
The cytoplasmic tail of the type I membrane protein CD44, which is a cell adhesion factor that is expressed in a 
broad range of tissues, has similarly been implicated in its cellular trafficking30. Upon expression of FLAG-tagged 
CD44, we detected a BB94-independent release of a 150-kDa species into the tissue culture supernatant (Fig. 4a). 
As observed for proTGFα , coexpression of CD44 with RHBDL4 increased the level of the late secretory path-
way form and its subsequent release into the media fraction, whereas the 100-kDa ER-resident species was not 
significantly affected (Fig. 4a,b). This implies that the ability of RHBDL4 to promote secretory trafficking is not 
restricted to proTGFα .
To challenge this idea, we assessed the effect of RHBDL4 on the Drosophila Rhomboid-1 substrate Spitz, 
which is the closest Drosophila homologue of proTGFα . Spitz has been previously reported to be a substrate 
of RHBDL2, another mammalian rhomboid protease; upon shedding and addition of complex type glycans in 
the Golgi, RHBDL2 sheds a 35-kDa form of Spitz (Fig. 4c)5,24. In contrast to the conventional shedding of Spitz 
induced by RHBDL2, co-expression of RHBDL4 led to the generation of a 47-kDa form in both cell extract and 
the media fraction. This higher molecular weight form contains EndoH-insensitive glycans, which implies its pas-
sage through the late secretory pathway. Interestingly, a virtually identical high-molecular-weight form of Spitz is 
generated also upon its coexpression with the Drosophila transport factor Star (Fig. 4d), consistent with the effect 
being caused by potentiating ER-to-Golgi transport.
proTGFα and CD44 are secreted by microvesicles. As well as conventional secretion of soluble lig-
ands, membrane proteins can be released from cells in microvesicles or exosomes, which are cytoplasm-filled 
vesicles derived from multivesicular bodies or the plasma membrane31. It has been reported previously that CD44 
and certain EGFR ligands can be secreted in exosomes in a signaling competent form32,33. To analyze whether the 
RHBDL4-dependent 37-kDa proTGFα and 150-kDa CD44 species are found in such extracellular microvesicles, 
the 175 000 g pellet of conditioned media from Hek293T cells co-expressing RHBDL4 and the respective ligand 
(Fig. 5a) were analyzed by sucrose flotation (Fig. 5b) which allows density-dependent separation of different types 
of vesicles, while protein aggregates are found in the pellet fraction34. We recovered higher molecular weight 
forms of both proTGFα and CD44 in fractions from the sucrose gradient (Fig. 5b) that indicated that they are 
associated with membrane-enclosed microvesicles. The secreted hormone prolactin was secreted in its soluble 
form and was not present in any vesicle-containing fraction (Fig. 5b), proving the effectiveness of the separation. 
Figure 4. RHBDL4 enhances ER-to-Golgi trafficking of various type I membrane proteins. (a) RHBDL4-
induced secretion of higher MW form is also observed for ectopically expressed CD44 (to a lower extend also 
by RHBDL1). (b) EndoH and PNGaseF treatment of cell extracts shows that higher molecular weight forms 
of CD44 (black arrow) localize to the late secretory pathway, whereas the lower molecular weight form (grey 
arrow) is ER-resident. Dot, deglycosylated form. (c) Cell-based rhomboid assay as in (a) using Drosophila Spitz. 
(d) RHBDL4-induced shift of Spitz to a higher molecular weight form mimics Star-mediated ER-to-Golgi 
transport. Asterisk, EndoH-insensitive fraction of Spitz.
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We conclude that RHBDL4 promotes the release of proTGFα and CD44 in membrane-enclosed extracellular 
vesicles.
Upon secretion of microvesicles, type I membrane proteins such as proTGFα are orientated with their ecto-
domain facing the extracellular space and their C-terminus pointing towards the cytoplasm-filled inside31. 
Consistent with this topology, proTGFα with a His-tag between the juxtamembrane ADAM17 cleavage site and 
the TM domain was recovered from the media by Ni-NTA resin (Fig. 5c), which recognizes the His-tag. In con-
trast, the slightly smaller form observed in absence of BB94 was not bound by Ni-NTA, confirming that it repre-
sents the soluble ectodomain released by canonical ADAM-catalyzed shedding. These results further support the 
conclusion that RHBDL4-dependent ER to Golgi trafficking of full-length proTGFα and CD44 promotes their 
release in microvesicles.
RHBDL4-induced ER-to-Golgi trafficking is signal regulated. Biosynthesis and trafficking of mem-
brane proteins are regulated by a variety of signals35,36 including growth-promoting GPCR pathways37. For exam-
ple, in a process known as transactivation, GPRC activation leads to physiological and pathological stimulation 
Figure 5. RHBDL4-induced stabilization of higher molecular weight forms leads to their detection 
in secreted microvesicles. (a) proTGFα -FLAG or CD44-FLAG were co-expressed in Hek293T cells with 
RHBDL4 (R4) or the catalytically inactive RHBDL4 mutant (R4-SA) in presence of 10 μ M BB94. After 
removing cell debris, conditioned media were subjected to ultracentrifugation. The 37-kDa form of proTGFα 
-FLAG and a subpopulation of CD44-FLAG were recovered in the 175,000 × g pellet fraction (p), whereas the 
trimmed FLAG-tagged TGFα pro-peptide (indicated by asterisk) was in the supernatant fraction (sn). t, total 
cell extracts. (b) proTGFα and CD44 from the 175,000 × g pellet fraction as obtained in (a) float in a sucrose 
gradient indicating that they are secreted by microvesicles. Soluble secreted prolactin serves as negative control 
as it is found in the supernatant (sn) fraction only. Sucrose density ranges from 1.06 g/l for the top (fraction 1) to 
1.25 g/l (fraction 9); sp, sucrose gradient pellet. (c) Released proTGFα -FLAG (black arrow) is trapped by a His-
tag that has been introduced between TACE-cleavage site and the juxtamembrane region. In contrast, FLAG-
tagged pro-peptide (asterisk) is not bound.
www.nature.com/scientificreports/
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Figure 6. RHBDL4-mediated proTGFα-secretion boost is enhanced by transactivation. (a) Exosome 
secretion of proTGFα -FLAG in COS7 cells ectopically expressing GRPR is stimulated by PMA or bombesin 
(bbs), mimicking the effect caused by RHBDL4 overexpression. In absence of BB94 (BB), transactivation by 
PMA and bbs also affects the extent of pro-peptide cleavage subsequently reducing the amount of secreted 
pro-peptide (asterisk) in the media fraction. (b) Upon transactivation of COS7 cells with bbs, the secreted 
37-kDa form of proTGFα -FLAG was processed to the 6-kDa mature form via a number of intermediates. Of 
note, due to a low expression the ER-resident 28-kDa form of proTGFα -FLAG was not detected (cf. Fig. 1a,g). 
(c) Time course of TGFα secretion after PMA stimulation of Hek293T ectopically expressing proTGFα 
-FLAG was performed in presence of BB94 (BB, 20 μ M), DCI (100 μ M) or both. (d) PMA and bbs-induced 
proTGFα -FLAG secretion boost can be suppressed by RHBDL4 knockdown in Hek293 T-REx cells expressing 
an inducible shRNA but not in control cells. This effect is rescued by ectopically expressed mouse RHBDL4 
(mRHBDL4-HA). Cytosolic GFP and ectopically expressed prolactin (Prl) serve as transfection and loading 
controls.
www.nature.com/scientificreports/
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of EGFRs by a secondary, autocrine release of their ligands (see ref. 38 for review). Release of EGFR ligands is also 
triggered by agents that stimulate downstream targets of GPCR signaling, including the phorbol ester phorbol 
12-myristate 13-acetate (PMA)15. The intracellular pathways that activate release of EGFR ligands during trans-
activation are not fully understood but, interestingly, treatment of mice by angiotensin (which activates a GPCR) 
leads to the generation of a 37-kDa form of TGFα in vivo14. Although this process so far has been seen in the 
light of ADAM-catalyzed shedding, the similarity to the RHBDL4 generated form of proTGFα prompted us to 
investigate whether transactivation might be linked to RHBDL4.
The peptide hormone bombesin activates the gastrin-releasing peptide receptor (GRPR)39. Treatment of COS7 
cells expressing the GRPR with bombesin enhanced the BB94-insensitive release of the 37-kDa form of proTGFα 
(Fig. 6a) . Similar BB94-insensitive release of full-length proTGFα was induced by PMA (Fig. 6a). All these forms 
were indistinguishable from the 37-kDa form generated by RHBDL4 overexpression (Fig. 6a). Although previous 
studies of EGFR transactivation have shown it to be BB94-sensitive, these have primarily assayed TGFα secretion 
by assaying EGFR activation12–14, which would not detect changes in microvesicle secretion of proTGFα , which 
is unable to stimulate the EGFR (see Fig. 1h). When ADAMs were not inhibited by BB94, the 37-kDa form of 
proTGFα disappeared, in concert with an increase in the 20-kDa membrane-anchored form (lacking the pro-
peptide), and the appearance of the 6-kDa soluble, bioactive ligand in the media fraction (Fig. 6b). We interpret 
this to mean that RHBDL4 can trigger microvesicle secretion of membrane tethered TGFα even when compet-
ing with metalloproteases that remove the prodomain and produce the bioactive soluble ligand. Importantly, in 
the absence of BB94, along with robust secretion of the 20-kDa species, traces of the 37-kDa species were also 
observed in the media fraction, indicating that trafficking into microvesicles is not an artifact of metalloprotease 
inhibition.
A central prediction of our model is that the observed release of the 37-kDa form would be inhibited by the 
serine protease inhibitor DCI, a rhomboid inhibitor40. This experiment is difficult, because robust release of proT-
GFα is detectable only several hours after stimulation (Fig. 6c), but DCI is toxic to cells over a similar time course. 
To help the cells survive, we expressed the antiapoptotic protein Bcl-XL41. As expected, DCI had a strong and 
specific inhibitory effect on the release of the 37-kDa form of proTGFα in response to PMA (Fig. 6c), suggesting 
that the effect of GPCR activation is dependent on RHBDL4 protease activity. Inhibition of ADAM proteases by 
BB94 blocked generation of the 6-kDa mature form, while both the 37-kDa and 20-kDa membrane-anchored 
forms were released by the microvesicle pathway (cf. Fig. 1a,g). Double treatment of cells with DCI and BB94, 
however, leads only to release of the 20-kDa form, indicating that it originates from the constitutive trafficking of 
TGFα that gets liberated from the pro-peptide even in presence of BB94 (but needs induced ADAM17 activity to 
be converted into the mature, soluble EGFR ligand22). Collectively, these results imply that GPCR signaling tunes 
ER exit of proTGFα in an RHBDL4-dependent manner, whereas microvesicle release of cargo that has reached 
the late secretory pathway is constitutive.
Consistent with a link between RHBDL4 and GPCR signaling, knockdown of RHBLD4 in Hek293 T-REx cells 
stably expressing a RHBDL4-specific shRNA17 reduced both PMA- and bombesin-induced release of proTGFα 
containing microvesicles, whereas no effect was observed in control cells lacking the shRNA (Fig. 6d). Ectopic 
expression of mouse RHBDL4 increased generation and release of the 37-kDa proTGFα form and rescued the 
knockdown. In contrast, secretion of the hormone prolactin was unaffected by manipulating RHBDL4 levels, 
demonstrating that the effect is specific and does not affect the constitutive secretory pathway.
In summary, our results show that in response to GPCR activation, RHBDL4 augments ER export of specific 
membrane protein cargo, thereby tuning the availability of important bioactive molecules including proTGFα . 
The underlying molecular mechanism, and the extent to which RHBDL4 contributes in vivo to EGFR transacti-
vation and other GPCR signaling outcomes, are now important questions.
Discussion
Ectodomain shedding is a universal mechanism that converts inactive TM proteins into soluble, bioactive signa-
ling molecules1,2. Drosophila rhomboid proteases have been shown to act as the key activators of EGFR ligands2, 
but the function of the mammalian rhomboids is still ill defined. Here we show that the ER-resident rhom-
boid protease RHBDL4 regulates a non-canonical mechanism in response to GPCR signaling, which leads to 
microvesicular secretion of membrane-tethered proTGFα and other TM cargo33. Consistent with several pre-
vious reports5,42,43, we show that proTGFα is not directly cleaved by RHBDL4, although this contradicts a more 
recent report that RHBDL4-catalyzes proTGFα ectodomain shedding16. We do not have a full explanation for the 
discrepancy between our data and that reported by Song et al. Nevertheless, we note that we can detected traces 
of a 17-kDa species that corresponds to what they interpret to be the product of RHBDL4 cleavage, but that, in 
our experiments, this band was still present when a catalytic mutant of RHBDL4 was used, and with proTGFα 
mutants predicted to be uncleavable. This leads us to conclude that the minor 17-kDa species is not the product 
of RHBDL4 cleavage. We also note that in uncropped western blots shown in supplementary data, Song et al.  
also detected secretion of larger forms of TGFα . The mechanism we describe adds a new process by which 
rhomboid-family proteins influence the EGFR signaling pathway.
ProTGFα is not significantly cleaved by RHBDL4, even when the protease is overexpressed, but instead it 
drives ER-to-Golgi transport of full-length membrane proTGFα and other cargoes by an unknown mechanism, 
which is dependent on RHBDL4 proteolytic activity. Given the ER localization of RHBDL4, we hypothesize that 
RHBDL4 might act on a factor involved in ER exit site regulation, hence explaining the ability to act on several 
TM cargoes (Fig. 7). The identity of this putative regulator, whether the RHBDL4-induced effect is mediated 
via regulatory degradation or proteolytic activation of this third party, and finally, the repertoire of TM car-
goes affected, remain important unsolved questions. This model is consistent with our observation that the cyto-
plasmic tail of proTGFα is necessary and sufficient to promote RHBDL4 regulated ER-to-Golgi trafficking. The 
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cytoplasmic tail of proTGFα has previously been shown to interact at various stages along the secretory pathway 
with regulatory factors including PDZ-domain proteins11.
Our results imply that ER-to-Golgi trafficking of proTGFα 16 is rate-limiting and that the majority of ectopi-
cally expressed proTGFα does not leave the ER but instead is targeted for proteasomal degradation (Fig. 7) (this 
study and ref. 22). Although the physiological relevance of this mechanism needs to be evaluated, it is attractive 
to speculate that secretion of TGFα and other biologically important signaling molecules is controlled at the 
earliest stage in the secretory pathway: at the level of the ER exit site. This principle of signal regulation at the level 
of ER-Golgi trafficking has already been described. For example, the putative cargo receptor Star regulates ER 
exit of the Drosophila TGFα homologue Spitz5. Interestingly in that case, rhomboid proteases have been impli-
cated in controlling the abundance of Star – a mechanism perhaps analogous to RHBDL4 control of proTGFα 44. 
In another example, iRhoms, catalytically inactive relatives of rhomboid proteases, regulate the ER-to-Golgi 
trafficking of ADAM1745–48. Although these examples are distinct, a consistent principle emerges: like Star and 
iRhoms, RHBDL4 tunes the secretion dynamics of client proteins from within the early secretory pathway.
We show that RHBDL4-mediated secretion control can be modulated by GPCR signaling. This is consistent 
with growing body of evidence supporting the view that certain rhomboid-family proteins are regulated by cel-
lular signaling49–51. We have previously shown that, in the context of ERAD, RHBDL4 specificity is governed by 
its cytoplasmic ubiquitin interacting motif, thereby linking recognition of unstable proteins to ER quality control 
and E3 ubiquitin ligases17. An important open question is whether there is a second regulatory mechanism of 
RHBDL4 activity or whether GPCR signaling modulates phosphorylation-dependent ubiquitination of putative 
RHBDL4 substrates as observed for the SCF E3 ubiquitin ligase complex during cell cycle52. There is clearly still 
much to understand mechanistically about how RHBDL4 controls trafficking.
It is now well recognized that EGFR transactivation acts as potent regulator of cell proliferation and cell 
invasion in many cell types including cancer cells, making it an attractive drug target38. The molecular mech-
anism, however, has not yet been fully resolved. Known molecular processes involved range from activation of 
ADAM-catalyzed shedding of growth factors12, to ligand-independent activation of receptor tyrosine kinases38, 
and iRhom mediated ER-Golgi trafficking of ADAM1747. RHBDL4 regulated trafficking provides a new mecha-
nism by which GPCRs can boost biosynthesis and secretion of EGFR ligands.
Importantly, a GPCR-induced 37-kDa higher molecular weight form of TGFα has previously been observed 
in mice in the context of chronic kidney disease14, suggesting that the mechanism that we revealed may have 
pathological relevance. Furthermore, release of EGFR ligands by exosomes has been observed in human breast 
and colorectal cancer cells33. Whereas Coffey and co-workers showed that the EGFR ligand amphiregulin is con-
tinuously released in exosomes in a signaling-competent state, leading to increased cancer cell invasion, they 
showed, like us, that TGFα associated with the same vesicles fraction showed no significant activity33. Since 
membrane-anchored TGFα does not act as a juxtacrine EGFR ligand53, this explains why we and others did not 
detect any significant activity of the microvesicle-associated forms (this study and ref. 33). Instead, we observed 
that the 37-kDa species and 20-kDa TGFα -TMD form (lacking the pro-peptide; see Fig. 1A) can be trimmed to 
the bioactive 6-kDa species.
We do not know the functional consequence of microvesicle release of membrane tethered clients, including 
TGFα . Release of bioactive ligands may occur from extracellular microvesicles by shedding events analogous to 
the canonical processing along the secretory pathway. Consistent with this hypothesis, active sheddases have been 
described to be also released by exosomes and soluble proteases have been described that can release TGFα from 
its membrane anchor32,54,55. Alternatively, microvesicles may become internalized by target cells to inactivate the 
EGFR ligand by lysosomal degradation33. Serial action of regulated trafficking events with ADAM-type sheddases 
generating bioactive ligands may be in balance with catabolic processes such as regulatory ERAD and lysosomal 
Figure 7. Model for RHBDL4 induced trafficking of proTGFα and secretion via microvesicles. Surplus 
proTGFα (indicated in blue) is constantly degraded by the ERAD pathway unless RHBDL4 removes an 
unknown ER-to-Golgi secretion block (indicated in red) probably by triggering degradation of a putative ER 
exit site (ERES) factor. Stimulating effect by GPCR and PKC that may increase RHBDL4 activity are highlighted 
by a green arrow.
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degradation. Association of RHBDL4/Rhbdd1 expression with colorectal cancer growth suggests that at least 
under pathogenic conditions this mechanism may promote EGFR signaling16.
Notably, we observed that the RHBDL4-mediated control of secretion dynamics is not restricted to proTGFα . 
CD44 is an important receptor for hyaluronic acid that mediates cell-to-cell and cell-to-matrix interaction, 
thereby controlling cell migration56. It is therefore conceivable that also CD44 levels need to be adapted to varying 
growth conditions. Likewise, changes in the CD44 expression level have been linked to numerous pathologies56. 
We do not know if there are further clients for the RHBDL4-controled secretion control, but as we hypothesize 
that RHBDL4 affects the cargo selection machinery, it seems likely. Overall, this work emphasizes the possibility 
that signaling pathways can regulate cargo export to buffer metabolic and signaling demands36. Our data also 
add weight to the importance of understanding the cell biological regulation of signaling pathways, and further 
highlights the central role of the rhomboid-like family in controlling the production of bioactive signals.
Methods
Plasmids. Unless otherwise stated proteins were cloned into pcDNA3.1+ (Invitrogen). Plasmids encoding 
mouse RHBDL1, RHBDL2, RHBDL3 and RHBDL4 tagged with an N-terminal triple HA-tag had been described 
previously9,57. Human proTGFα 5 was used either untagged or tagged in the pro-peptide between residue 31 and 
32 by a triple FLAG-tag (FLAG3). Rhomboid mutants and proTGFα -FLAG3 mutants were generated by Quick-
Change site-directed mutagenesis (Stratagene). Deletion constructs proTGFα Δ 4 and proTGFα Δ 31 were gen-
erated by subcloning the respective region of the open reading frame. The construct proTGFα -CNXTMD was 
generated by overlap extension PCR58, replacing amino acid 99 to 121 of proTGFα by residue 482 to 504 of 
human calnexin17. CNX-TGFα tail was generated accordingly by replacing amino acids 505 to 592 of calnexin 
by residues 122 to 160 of proTGFα . The juxtamembrane poly-His-tag in proTGFα -H8 was introduced at posi-
tion 94 of proTGFα . The open reading frames encoding human CD44 (IMAGE cDNA clone 4865289) and 
mouse S1P without pro-peptide (IMAGE cDNA clone 5310414) were cloned without their signal peptides into 
pcDNA3-based expression vector containing the Spitz signal peptide fused to a FLAG3-tag9. RHBDL4-GFP wt, 
the catalytic S144A mutant and the catalytic mutant with a defective UIM (S144A/L274A/L278A) were based 
on the monomeric variant of pEGFP-N1 (Clontech) as had been described previously17. Constructs for RFP-
tagged RHBDL4 were generated by subcloning into pTagRFP-N (Evrogen). Constructs for mouse RHBDL2-
GFP57, human pTα -FLAG317, human prolactin24, Drosophila Spitz-FLAG324, Drosophila Star5 and the ER marker 
RFP-KDEL59 were previously described. Mouse GRPR (IMAGE cDNA clone 40047100) was cloned untagged. 
The construct coding human Bcl-XL was a gift from Seamus Martin60.
Cell Lines and Transfection. Hek293T, A431, and COS7 cells were grown in DMEM (Invitrogen), 
HCT116 cells in McCoy’s 5a medium (Invitrogen) supplemented with 10% fetal bovine serum at 37 °C in 5% 
CO2. Inducible stably transfected Hek293 T-Rex cells (Invitrogen) expressing an RHBDL4-specific shRNA were 
grown in presence of blasticidin (10 μ g/ml) and G418 (0.5 mg/ml). Knockdown was induced with 1 μ g/ml dox-
ycycline. Transient transfections were performed using FuGENE 6 (Roche) or 25 kDa linear polyethylenimine 
(Polysciences)61 as described5,62. Typically, 250 ng plasmid encoding substrate/client and 25 ng plasmid encoding 
a rhomboid were used per well of a 6-well plate. Total transfected DNA (1 μ g/well) was held constant by the 
addition of empty plasmid. For polyethylenimine transfection commonly double the amount of DNA was used. 
Sixteen hours post transfection, medium was replaced with serum-free Opti-MEM medium (Invitrogen) con-
taining 10 µ M BB94 (British Biotech) unless otherwise stated. For activation of endogenous rhomboid activity, 
1 μ M PMA (Sigma) or 100 nM bombesin (Sigma) was added to cell medium. For inhibitor studies, the indicated 
protease inhibitors (Calbiochem), diluted in DMSO, were compared with a carrier only. Medium was harvested 
typically after 24 to 30 hours; for inhibitor studies using DCI, a time course with 0 minutes, 30 minutes and 4 hour 
timepoints was performed. Cells were solubilized in SDS-sample buffer and analyzed by SDS-PAGE (see below). 
EndoH (New England Biolabs) and PNGaseF (New England Biolabs) treatment of SDS-solubilized cell extracts 
was performed according to the manufacturer’s instructions. Conditioned media were centrifuged for 5 minutes 
at 500 g followed by 10 minutes at full speed in a microfuge to remove cell debris, and subsequently proteins in 
the supernatant were precipitated by adding trichloroacetic acid (TCA) to 10%. The precipitate was recovered 
by centrifugation, washed with acetone and dissolved in SDS-PAGE sample buffer and analyzed by SDS-PAGE 
and western blotting (see below). Alternatively to TCA precipitation, proTGFα -H8 in conditioned medium was 
captured by metal-chelate chromatography using Ni-NTA agarose beads (Qiagen) in the presence of 20 mM 
imidazole at pH 8.0. Subsequently beads were washed with 20 mM Tris-Cl pH 8.0, 50 mM imidazole, eluted with 
SDS-sample buffer and analyzed by western blotting.
EGFR Activation Assay. Subconfluent A431 cells were grown in serum free medium for 24 hours, followed 
by incubation with conditioned medium that had been harvested from a cellular RHBDL4-cleavage assay using 
untagged proTGFα (see above). After 10 minutes incubation at 37 °C, cells were lyzed in SDS-sample buffer and 
analyzed by western blotting (see below).
Pulse-label Chase Analysis. For pulse-label chase experiments, transfected Hek293T cells were starved for 
60 min in methionine/cysteine free DMEM (Invitrogen) supplemented with 10% dialysed fetal calf serum, then 
metabolically labelled for 10 min with 55 μ Ci/ml 35S-methionine/cysteine protein labeling mix (Perkin Elmer). 
Cells were rinsed with PBS, then chased in normal growth medium. At the end of the chase period cells were 
rinsed with PBS and solubilized in 1% Triton X-100 followed by immunoprecipitation of FLAG-tagged proteins 
as described below. Samples were analyzed by SDS-PAGE and labeled proteins were visualized by a FLA-7000 
phosphorimager (Fuji).
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Immunoprecipitation. For substrate trapping, RHBDL4-GFP expressing Hek293T cells were solubilized 
with 1% Triton X-100 in IP buffer (50 mM HEPES-KOH, pH 7.4, 150 mM NaCl, 2 mM MgOAc2, 10% glyc-
erol, 1 mM EGTA), containing EDTA-free complete protease inhibitor cocktail (Roche) and 10 μ g/ml PMSF. 
Cell lysates were cleared by centrifugation at 20,000 g for 15 min and subsequently pre-incubated for 1 h on 
BSA-coupled sepharose beads. Anti-GFP immunoprecipitation was performed using a GFP-specific single chain 
antibody fragment coupled to NHS-activated sepharose beads as described63. Immunoprecipitates were washed 
three times in IP buffer, containing 0.1% Triton X-100 and eluted in SDS sample buffer and analyzed by western 
blotting (see below).
Separation of Microvesicles by Continuous Sucrose Gradient Centrifugation. Microvesicles were 
isolated from conditioned medium by sucrose gradient centrifugation, as has been described34. All steps were 
performed at 4 °C. In brief, conditioned medium from 4 × 10 cm dishes of confluent cells was collected 40 h 
after transfection and was centrifuged at 400 g for 10 minutes, followed by 20,000 g for 20 minutes to remove cell 
debris. Subsequently, extracellular vesicles were pelleted by centrifugation at 175,000 g for 60 minutes and washed 
two times with PBS. The pellet was resuspended in 100 μ l PBS and 1 ml of 2.5 M sucrose solution (dissolved in 
25 mM HEPES-KOH, pH 7.2) was added. For the sucrose gradient, 6 ml of 2 M sucrose was overlaid with 6 ml of 
0.25 M sucrose in a polycarbonate centrifuge tube and mixed using a Gradient Master (BioComp Instruments). 
The sucrose gradient was underlaid with the dissolved vesicle-containing pellet and centrifuged using a SW40 Ti 
swinging bucket rotor at 100,000 g for 16 h. Subsequently, nine 1.5 ml fractions were collected and precipitated 
with 20% TCA and analyzed by western blotting (see below).
Antibodies. The following antibodies were used: mouse monoclonal anti-FLAG (M2; Sigma), mouse mon-
oclonal anti-HA (HA.11; Covance), mouse monoclonal anti-TGFα (134A-2B3; Oncogene), mouse monoclonal 
anti-phospho-EGFR antibody (9H2; Upstate), polyclonal rabbit anti-EGFR (1005; Santa Cruz Biotechnology), 
polyclonal rabbit anti-Prl (Serotec), mouse monoclonal anti-BAP31 (A1/182; Alexis). Polyclonal rabbit anti-GFP 
antibody was a gift from Dirk Görlich. Polyclonal rabbit antibody specific for RHBDL4 has been described pre-
viously17. For affinity purification the GST fusion protein was coupled to HiTrap NHS-activated HP (Amersham 
Biosciences) and used to purify the antibody according to standard protocols.
Microscopy. For life cell analysis, HCT116 cells were analyzed by confocal microscopy using a LSM 780 
confocal microscope (Zeiss). For immunofluorescence analysis, COS7 cells were fixed in methanol at − 20 °C 
for 5 minutes followed by acetone at − 20 °C for 45 seconds. Cell were washed with PBS and blocked with 20% 
fetal calf serum in PBS, cells were probed with affinity-purified anti RHBDL4 antibody (1:500; see above) 
and anti BAP31 antibody (1:1000). After staining with fluorescently labeled secondary antibody (Santa Cruz 
Biotechnology), slides were analyzed using the LSM 780 confocal microscope.
Western Blotting. Transfected cells, TCA-precipitated tissue culture supernatants and fractions from 
sucrose gradient centrifugation were solubilized in SDS sample buffer (50 mM Tris-Cl pH 6.8; 10 mM EDTA, 5% 
glycerol, 2% SDS, 0.01% bromphenol blue) containing 5% β -mercaptoethanol. All samples were incubated for 
15 min at 65 °C, resolved on Tris-glycine SDS-PAGE followed by western blot analysis using enhanced chemilu-
minescence to detect bound antibodies. In order to detect the 6-kDa form of TGFα , proteins were transferred 
on PVDF membrane with 0.2 μ m pore size (Millipore) and probed with TGFα -specific antibody (1:100). For 
detection of phosphorylated EGFR, PVDF membranes were blocked in 3% BSA in TBS-Tween supplemented 
with 200 μM NaVO3 and probed with anti phospho-EGFR antibody (1:2000). Subsequently membranes were 
stripped and reprobed with the EGFR-specific antibody (1:1000). For detection, X-ray films or the LAS-4000 
system (Fuji) were used.
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